Dissociation of local anti-inflammatory effect and systemic effects of mometasone furoate in mice

References

• Edwards, T.B. Effectiveness and safety of beclomethasone dipropionate, an intranasal corticosteroid, in the treatment of patients with allergic rhinitis. Clin Ther. 1995, 17 (6), 1032–1041.
   PubMedGoogle Scholar
• Mortimer, K.J., Tattersfield, A.E. Benefit versus risk for oral, inhaled, and nasal glucocorticosteroids. Immunol Allergy Clin North Am. 2005, 25 (3), 523–539.
   PubMedGoogle Scholar
• Prakash, A., Benfield, P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998, 55 (1), 145–163.
   PubMedGoogle Scholar
• Baldwin, C.M., Scott, L.J. Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs. 2008, 68 (12), 1723–1739.
   PubMedGoogle Scholar
• McCormack, P.L., Plosker, G.L. Inhaled mometasone furoate. A review of its use in persistent asthma in adults and adolescents. Drugs. 2006, 66 (8), 1151–1168.
   PubMedGoogle Scholar
• Karpel, J.P., Nelson, H. Mometasone furoate dry powder inhaler: A once-daily inhaled corticosteroid for the treatment of persistent asthma. Curr Med Res Opin. 2007, 23 (11), 2897–2911.
   PubMedGoogle Scholar
• Hübner, M., Hochhaus, G., Derendorf, H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005, 25 (3), 469–488.
   PubMedGoogle Scholar
• Tonelli. G., Thibault, L., Ringler, I. A bio-assay for the concomitant assessment of the antiphlogistic and thymolytic activities of topically applied corticoids. Endocrinology. 1965, 77 (4), 625–634.
   PubMedGoogle Scholar
• Guo, L., Ye, C., Chen, W., et al. Anti-inflammatory and analgesic potency of carboxyamidotriazole, a tumorostatic agent. J Pharmacol Exp Ther. 2008, 325 (1), 10–16.
   PubMedGoogle Scholar
• You, Z., Heiman, A.S., Chen, M., Lee, H.J. Novel steroid spiro enones: Condensation of prednisolone derivatives with diethyl oxalate. Steroids. 2000, 65 (2), 109–115.
   PubMedGoogle Scholar
• Park, K.K., Ko, D.H., You, Z., et al. In vitro anti-inflammatory activities of new steroidal antedrugs: [16α,17α-d] Isoxazoline and [16α,17α-d]-3’-hydroxy-iminoformyl isoxazoline derivatives of prednisolone and 9α-fluoroprednisolone. Steroids. 2006, 71 (3), 183–188.
   PubMedGoogle Scholar
• Towbin, H., Pignat, W., Wiesenberg, I. Time-dependent cytokine production in the croton oil-induced mouse ear oedema and inhibition by prednisolone. Inflamm Res. 1995, 44 (Suppl. 2), S160–S161.
   Google Scholar
• Arfsten, D.P., Johnson, E.W., Thitoff, A.R., et al. Acute and subacute dermal toxicity of break-free CLP: A weapons cleaning and maintenance compound. J Appl Toxicol. 2005, 25 (4), 318–327.
   PubMedGoogle Scholar
• Pujols, L., Mullol, J., Torrego, A., Picado, C. Glucocorticoid receptors in human airways. Allergy. 2004, 59 (10), 1042–1052.
   PubMedGoogle Scholar
• Smith, C.L., Kreutner, W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998, 48 (9), 956–960.
   PubMedGoogle Scholar
• Tonomura, N., McLaughlin, K., Grimm, L., Goldsby, R.A.; Osborne, B.A. Glucocorticoid-induced apoptosis of thymocytes: Requirement of proteasome-dependent mitochondrial activity. J Immunol. 2003, 170 (5), 2469–2478.
   PubMedGoogle Scholar
• Ashwell, J.D., Lu, F.W., Vacchio, M.S. Glucocorticoids in T cell development and function. Annu Rev Immunol. 2000, 18, 309–345.
   PubMed Web of Science ®Google Scholar
• Herold, M.J., McPherson, K.G., Reichardt, H.M. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci. 2006, 63 (1), 60–72.
   PubMedGoogle Scholar
• Cohen, J.J. Glucocorticoid-induced apoptosis in the thymus. Semin Immunol. 1992, 4 (6), 363–369.
   PubMedGoogle Scholar
• Engler, H., Stefanski, V. Social stress and T cell maturation in male rats: Transient and persistent alterations in thymic function. Psychoneuroendocrinology. 2003, 28 (8), 951–969.
   PubMedGoogle Scholar
• Ma, K., Mallidis, C., Bhasin, S., et al.. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab. 2003, 285 (2), E363–E371.
   Google Scholar
• Newton, R. Molecular mechanisms of glucocorticoid action: What is important? Thorax. 2000, 55 (7), 603–613.
   PubMedGoogle Scholar
• Munck. A., Guyre, P.M. Glucocorticoid physiology, pharmacology and stress. Adv Exp Med Biol. 1986, 196, 81–96.
   PubMedGoogle Scholar
• Daley-Yates, P.T., Price, A.C., et al. Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol. 2001, 51 (5), 400–409.
   PubMedGoogle Scholar
• Daley-Yates, P.T., Kunka, R.L., Yin, Y., et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol. 2004, 60 (4), 265–268.
   PubMedGoogle Scholar
• Boner, A.L. Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children. J Allergy Clin Immunol. 2001, 108 (1 Suppl.), S32–S39.
   Google Scholar
• Affrime, M.B., Cuss, F., Padhi, D., et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol. 2000, 40 (11), 1227–1236.
   PubMedGoogle Scholar
• Affrime, M.B., Kosoglou, T., Thonoor, C.M., et al. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest. 2000, 118 (6), 1538–1546.
   PubMedGoogle Scholar